GlassScriptPhysician profile
Mary Ellen Pelletier
NPI 1336219054
$3,085.17
in general payments reported to CMS, 2019-2025
21 companies · $123 in 2025
The $123 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $610 · 2021: $569 · 2022: $240 · 2023: $681 · 2024: $704 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $977.89 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $794.46 | 2020-2025 | Eliquis, Camzyos |
| Abbvie INC. | $307.98 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $205.50 | 2023-2024 | Soliris, Ultomiris |
| Pfizer INC. | $136.87 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.95 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $81.21 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $81.05 | 2023 | |
| Merck Sharp & Dohme LLC | $67.21 | 2024-2025 | Zerbaxa, Dificid, Prevymis |
| Smith+Nephew, INC. | $43.71 | 2019 | |
| Shionogi INC | $42.08 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $34.07 | 2024 | Giapreza, Xerava |
| Exact Sciences Corporation | $33.24 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $32.39 | 2024 | Veozah |
| Vapotherm INC | $25.27 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.83 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $21.52 | 2025 | |
| Ucb, INC. | $17.75 | 2019 | |
| Daiichi Sankyo INC. | $16.40 | 2021 | |
| Gilead Sciences, INC. | $16.01 | 2023 | Veklury |
| Lilly USA, LLC | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ellen Pelletier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.